新一代低血糖药对妄,抑郁,痴呆和昏迷的度依赖性保护作用:来自网络元分析的证据
Ping-Tao Tseng1,2,3,4, Bing-Yan Zeng2,5, Chih-Wei Hsu6
1Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
Journal of the Royal Society of Medicine
|December 8, 2025
概括
类似葡萄糖类-1 (GLP-1) 受体激活剂和-葡萄糖共载体2 (SGLT2) 抑制剂显示出神经保护的潜力. 高剂量的达帕格利弗洛辛减少了妄想和抑郁症,而杜拉格卢和利拉格卢在这个网络元分析中改善了认知能力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 新兴证据表明GLP-1受体激动剂和SGLT2抑制剂的神经保护作用.
- 这些药物对神经精神病结局的比较疗效尚不清楚.
- 这个网络元分析 (NMA) 解决了这一知识缺口.
研究的目的:
- 评估GLP-1受体激动剂和SGLT2抑制剂对精神状态变化的差异影响.
- 为了比较这些疗法在预防妄想,抑郁,痴呆和昏迷方面的疗效.
- 为了识别特定的药物神经保护特征.
主要方法:
- 使用随机对照试验 (RCT) 数据进行了一项频率网络元分析 (NMA).
- 用贝叶斯的NMA框架来验证发现的可靠性.
- 包括的试验招募了没有基线认知或精神疾病的个人.
主要成果:
- 分析了62个与200,068名参与者的RCT.
- 高剂量达帕格利弗洛辛 (10毫克/天) 显著降低了妄想和抑郁症,特别是在2型糖尿病患者中.
- 杜拉格卢提德和利拉格卢提德与认知能力的改善有关;对痴呆或昏迷没有观察到任何好处.
结论:
- SGLT2 抑制剂,特别是高剂量的达帕格利弗洛辛,可以减轻妄想和抑郁的发作.
- GLP-1受体激动剂,特别是杜拉格卢和利拉格卢,可能会增强认知功能.
- 这些发现支持在患有神经精神疾病风险较高的人群中使用抗高血糖药物治疗的特异性考虑.
相关概念视频
Hypoglycemia and Glucagon
778
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
778
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572
Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Sedatives and Hypnotics Drugs: Miscellaneous Agents
479
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
479


